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Abstract
Background: Human African trypanosomiasis (HAT), a major parasitic disease spread in Africa, urgently needs novel targets
and new efficacious chemotherapeutic agents. Recently, we discovered that 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-
yl]morpholine (compound 1) exhibits specific antitrypanosomal activity with an IC50 of 1.0 mMo nTrypanosoma brucei
rhodesiense (T. b. rhodesiense), the causative agent of the acute form of HAT.
Methodology/Principal Findings: In this work we show adenosine kinase of T. b. rhodesiense (TbrAK), a key enzyme of the
parasite purine salvage pathway which is vital for parasite survival, to be the putative intracellular target of compound 1
using a chemical proteomics approach. This finding was confirmed by RNA interference experiments showing that down-
regulation of adenosine kinase counteracts compound 1 activity. Further chemical validation demonstrated that compound
1 interacts specifically and tightly with TbrAK with nanomolar affinity, and in vitro activity measurements showed that
compound 1 is an enhancer of TbrAK activity. The subsequent kinetic analysis provided strong evidence that the observed
hyperactivation of TbrAK is due to the abolishment of the intrinsic substrate-inhibition.
Conclusions/Significance: The results suggest that TbrAK is the putative target of this compound, and that hyperactivation
of TbrAK may represent a novel therapeutic strategy for the development of trypanocides.
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Introduction
Trypanosomiases belong to the major parasitic diseases spread
throughout the world. Human African Trypanosomiasis (HAT;
sleeping sickness) is a vector-borne parasitic disease transmitted by
a protozoan parasite of the genus Trypanosoma via the bites of
infected tsetse flies. Two different forms of HAT are known. The
chronic form is caused by Trypanosoma brucei gambiense (T. b.
gambiense) infection whereas Trypanosoma brucei rhodesiense (T. b.
rhodesiense) is responsible for the acute form of the disease. Both
forms of HAT develop in two stages. After the bite, parasites first
distribute to the blood, lymph and peripheral organs (stage 1), then
spread to the central nervous system (stage 2) where they cause
serious neurological disorders. Leaving infected people untreated,
HAT is invariably fatal. Today, sleeping sickness threatens
millions of people in 36 countries of sub-Saharan Africa [1,2].
The estimated number of deaths annually is currently between
50’000 and 70’000 [3].
Four drugs (pentamidine, melarsoprol, eflornithine and sura-
min) are registered for the treatment of sleeping sickness and
provided free of charge to endemic countries through a World
Health Organization (WHO) private partnership. The type of
treatment depends on the stage of the disease. Pentamidine and
suramin are used for first stage treatment of T. b. gambiense and T.
b. rhodesiense sleeping sickness, respectively. The drugs capable to
treat the second stage infections are more toxic and complicated to
administer, and they need to cross the blood-brain barrier to reach
the parasites within the central nervous system. Melarsoprol,
which is effective against both forms of HAT, derives from arsenic
and has many severe side effects, the most dramatic (prevalence 5
to 15%) being a reactive encephalopathy (encephalopathic
syndrome) which can be fatal in 3–10% of affected patients. An
increase of resistance to the drug has been observed in several foci
particularly in central Africa. Eflornithine is less toxic than
melarsoprol, but it is only effective against T. b. gambiense sleeping
sickness, and a strict and complicated regimen has to be applied. It
is evident that therapy of HAT relies on few drugs which are
associated with severe side effects. There has been a revival of drug
research and development regarding HAT compared to the last 15
years, and a number of drug development projects are currently
ongoing. Unfortunately, the development of the only compound
(pafuramidine) having advanced to phase III clinical trials [4,5] for
www.plosntds.org 1 August 2009 | Volume 3 | Issue 8 | e506stage one treatment was discontinued [6]. Thus, novel targets and
new efficacious chemotherapeutic agents are urgently needed.
Recently we reported the synthesis and evaluation of new 4-[5-
(4-phenoxy-phenyl-2H-pyrazol-3-yl]morpholine derivatives
against several parasites [7]. One of the compounds, 4-[5-(4-
phenoxy-phenyl-2H-pyrazol-3-yl]morpholine (Fig. 1, compound
1), exhibited good activity toward T. b. rhodesiense with an IC50 of
1 mM and low cytotoxicity [7]. This finding prompted us to
address the question regarding the cellular target and the
molecular mechanism underlying the observed toxicity toward
the parasite. To this end, here we report a chemical proteomics
approach that led to the identification of adenosine kinase as the
putative target. Subsequent biochemical and biophysical charac-
terization with respect to compound 1 binding as well as drug
sensitivity tests on the corresponding knock-down strain allowed its
validation and suggested hyperactivation of adenosine kinase as
the molecular mechanism underlying the biological activity.
Methods
Preparation of T. b. rhodesiense lysate
The parasites collected from mouse blood were lysed with lysis
buffer consisting of 20 mM Hepes, 150 mM NaCl, 1% Triton X-
100, 2 mM tris(2-carboxyethyl)phosphine (TCEP), 10% glycerol,
1 ml/ml protease inhibitor cocktail, at pH 7.5. To this end, the
suspension of the purified cells (2.56610
9 trypanosomes) in 160 ml
PBS were treated with 40 ml lysis buffer concentrate (five fold).
After short intervals of sonication the mixture was centrifuged for
10 min at 14’000 g, the supernatant was recovered and stored in
aliquots at -20uC. The total protein concentration was measured
using Bradford dye assay [8], and the lysate was further diluted to
the desired concentration using lysis buffer. All protocols and
procedures used in the current study were reviewed and approved
by the local veterinary authorities of the Canton Basel-Stadt
(Switzerland).
Affinity chromatography and identification by mass
spectrometry
Compounds 2, 3, and 4 (Fig. 1) were immobilized via the
primary or secondary amino groups (Fig. S1) on epoxy-activated
agarose providing a 12-atoms spacer (1,4-bis(2:3-epoxypropoxy)-
butane). Swollen and thoroughly washed matrix was resuspended
in two to three volumes of 12.5–50 mM ligand dissolved in 50%
DMF/50 mM Na2CO3, 50 mM NaCl, pH 9.5. Coupling was
performed for 16–72 h at 25–40uC. After 4 to 5 washes with 50%
DMF/50 mM Na2CO3, 50 mM NaCl, pH 9.5, remaining
reactive groups were blocked with 1 M ethanolamine (pH 8)
and thoroughly washed with low/high pH buffers. A control
matrix was prepared without ligand and treated as described
above. Direct absorbance scans of the immobilized ligand on the
matrix resuspended in 50% glycerol solution (v/v) clearly
confirmed successful coupling (data not shown). The amount of
inhibitor bound to the matrix was determined by back calculation
of amount of compound applied and amount recovered by UV
determination. Routinely 20–45 mmol/ml compound were bound.
The resin was incubated in 2.5 volumes of T. b. rhodesiense total cell
Figure 1. Chemical structures of compounds used in this study. The title compound 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine (1)
and its amino substituted derivatives 4-[4-(5-morpholine-4-yl-1H-pyrazol-3-yl)-phenoxy]phenylamine (2), 4-[5-morpholine-4-yl-3-(4-phenoxyphenyl)-
pyrazol-1-yl]phenylamine (3) and 1-[5-(4-phenoxyphenyl-2H-pyrazol-3-yl]piperazine (4) are presented. 3-(4-phenoxyphenyl)-1H-pyrazole (5) showed
very low antiparasitic activity (IC50 of .65 mM) as well as general toxicity (IC50 of .136 mM), therefore it was used as negative control for the
biochemical, biophysical and compound sensitivity tests.
doi:10.1371/journal.pntd.0000506.g001
Author Summary
Human African trypanosomiasis (HAT), a devastating and
fatal parasitic disease endemic in sub-Saharan Africa,
urgently needs novel targets and efficacious chemother-
apeutic agents. Recently, we discovered that 4-[5-(4-
phenoxyphenyl)-2H-pyrazol-3-yl]morpholine exhibits spe-
cific antitrypanosomal activity toward T. b. rhodesiense, the
causative agent of the acute form of HAT. Here we applied
a chemical proteomics approach to find the cellular target
of this compound. Adenosine kinase, a key enzyme of the
parasite purine salvage pathway, was isolated and
identified as compound binding partner. Direct binding
assays using recombinant protein, and tests on an
adenosine kinase knock-down mutant of the parasite
produced by RNA interference confirmed TbrAK as the
putative target. Kinetic analyses showed that the title
compound is an activator of adenosine kinase and that the
observed hyperactivation of TbrAK is due to the abolish-
ment of the intrinsic substrate-inhibition. Whereas hyper-
activation as a mechanism of action is well known from
drugs targeting cell signaling, this is a novel and hitherto
unexplored concept for compounds targeting metabolic
enzymes, suggesting that hyperactivation of TbrAK may
represent a novel therapeutic strategy for the develop-
ment of trypanocides.
TbrAK as Putative Target with Novel Mechanism
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washing with lysis buffer (four times), the matrix was heated at
95uC for 5 min with Laemmli sample buffer, directly loaded and
separated by 12% SDS-PAGE. Resolved proteins were visualized
by silver staining. The control matrix was incubated with the same
amount of lysate and treated equally. Proteins bands were excised
from the gels and fragments resulting from trypsin digestion were
analyzed by LC/ESI/MS/MS-QTOF mass spectrometry. Data-
base searches were performed by using the ProteinLynx Global
Server (all species) and Mascot (other eukaryotes) search programs.
A score .46 indicates identity (p,0.05).
HPLC activity assay for TbrAK
TbrAK catalyzes the ATP-dependent phosphorylation of the
59-hydroxyl moiety of adenosine to form AMP and ADP. The
activity assay was based on HPLC separation of substrate and
products (adenosine, AMP, ADP, and ATP). The mobile phase
consisted of 35 mM KH2PO4, 6 mM tetrabutylammonium
hydrogensulfate, (pH 7.0, adjusted with KOH), 125 mM EDTA,
and 1% (v/v) acetonitrile. The separation was performed
isocratically at a flow-rate of 1.5 ml/min and monitored at
254 nm. The standard reaction in 75 ml total volume containing
0.5 mM ATP, 0.5 mM adenosine, 0.5 mM MgCl2, 1% DMSO in
buffer E1 (20 mM Hepes, 150 mM NaCl, pH 7.0) was started
with the addition of 2 mg TbrAK (final concentration 0.7 mM) and
incubated at 37uC for 10 min while shaking vigorously (600 rpm).
To measure the influence of compound 1–5 on TbrAK activity,
DMSO was replaced in the assay mixture by compound 1–5 so
that the final concentration of 1% DMSO was maintained while
the concentration of compound could be varied in the range of 0–
1 mM depending on solubility. All reactions were stopped by
adding 75 ml mobile phase. 50 ml of the sample volume were
injected for analysis and the resulting ADP/ATP ratios were
calculated and used as a measure of activity. For comparative
reasons the activity recorded in absence of compound was set to
100%. The mean of three independent measurements are
reported.
Calorimetric measurements
Isothermal titration calorimetry (ITC) was employed to
elucidate the binding affinity of compound 1 toward TbrAK. All
solutions were degassed for 5 min with gentle stirring under
vacuum. TbrAK was dialyzed into buffer E2 (20 mM Tris,
150 mM NaCl, pH 7.5, 5% glycerol), diluted to 7 mM and
supplemented with 1% DMSO, filtered and filled into the sample
cell. The ligand solution was prepared by diluting a stock solution
of compound 1 or 5 in DMSO with buffer E2 to give a final
concentration of 150 mM and 1% DMSO. The final ligand
solution was filtered before use. A titration experiment consisted of
a first control injection of 1 ml followed by 27 injections, each of
10 ml and 20 s duration, with a 4-min interval in between. Raw
data were collected, corrected for ligand heats of dilution,
integrated and fit to the two-set non-interacting binding sites
model using the OriginH software supplied with the instrument.
The measurements were performed at least in duplicate.
Radiometric assay for kinetic study of TbrAK
Kinetic constants for adenosine phosphorylation by TbrAK
were obtained by monitoring the conversion of [2-
3H]adenosine to
[2-
3H]AMP. Reactions were executed at 37uC in a final volume of
30 ml containing 20 mM Hepes (pH 7.0), 50 mM NaCl, 167 mM
ATP, 167 mM MgCl2, 0.34% BSA, and 0.34% DMSO. To
measure the influence of compound 1 to kinetic parameters,
DMSO was omitted in the assay mixture and 1 was added from a
10 mM stock solution in DMSO to give a final concentration of
33.4 mM and 0.34% DMSO. The concentration of [2-
3H]aden-
osine (0.1–12 mM) was chosen in consideration of Michaelis–
Menten conditions for initial velocity measurements. The reaction
was started by the addition of 1 ng (0.88 nM) TbrAK. The
reactions were incubated and 5 ml aliquots were spotted on 5 mm
diameter DE81-cellulose disks placed in a 96-well plate to stop the
reaction. The disks were washed 3 times with 250 ml5 m M
ammonium formate, once with H2O, transferred to scintillation
vials, and then soaked with 2 ml of a displacement solution
(100 mM HCl, 200 mM KCl) and gently shaken for 1 minute to
elute the phosphorylated products [9]. After adding 10 ml
scintillation liquid, the samples were counted in scintillation
counter. Km and Vmax with respect to adenosine and Ki for
adenosine substrate-inhibition in absence and presence of
compound 1 were determined by non-linear fit of the data to
the substrate-inhibition model described elsewhere [10]. The
results are based on three independent series with each data point
measured in triplicates.
Genetic knock-down of TbAK and drug sensitivity tests
The construction of the T. b. brucei adenosine kinase gene knock-
down mutant has been described recently [11]. Expression of a
stem-loop construct targeting TbAK was induced by addition of
10 mg/ml tetracycline to the medium. Down-regulation of TbAK
expression was verified by Northern blotting. Parasites were
cultivated and drug sensitivity was tested using the Alamar blue
test [12]. IC50 values were calculated by nonlinear fitting to the
sigmoidal dose-response curve using OriginH software. The assays
were performed in triplicates for at least four times.
Other methods
Origin of supplies as well as protocols for purification of
recombinant proteins, the spectroscopic assay for TbrGAPDH,
the radiometric assay for TbrAK, and the thermal denaturation
assay are described in the Supporting Information (Text S1).
Results
Compound choice and immobilization
In order to isolate and identify the intracellular target(s) of
compound 1 in T. b. rhodesiense we decided to immobilize the
compound and to isolate their target(s) by an affinity chromatog-
raphy approach. The binding mode of 1 to the putative target(s)
being unknown, we immobilized three derivatives of compound 1
(Fig. 1, compound 2–4), each containing an additional primary or
secondary amino group at different positions [7], and linked them
to epoxy-activated agarose. The primary aromatic amine in
compound 2 and 3, and the secondary amino group in the
piperazine moiety of compound 4 react with the terminal epoxy
group of the activated agarose, providing an uncharged,
hydrophilic and very stable 12-atoms spacer (see Fig. S1). The
direct linkage of compound 1 to epoxy-activated agarose via the
pyrazole moiety was not likely to occur under the applied
experimental conditions due to the weak nucleophilicity of the
heterocycle for epoxide-based alkylation which in general requires
rather drastic conditions, i.e. prolonged heating at high temper-
ature with the concomitant use of a strong base [13]. Direct
absorbance scans of the immobilized ligand on the matrix
resuspended in 50% glycerol solution (v/v) confirmed successful
coupling (data not shown). Routinely 20–45 mmol/ml compound
were bound. Our recent evaluation of compound 1 and its
derivatives clearly indicated the morpholine moiety to be
important for the biological effect [7] which is corroborated by
TbrAK as Putative Target with Novel Mechanism
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low antiparasitic activity (IC50 of .65 mM). Therefore compound
5 was chosen as negative control.
Immobilized compounds bind TbrGAPDH and TbrAK
The total parasite lysate was prepared, loaded on the matrices
and unbound material was removed as outlined in the Methods
section. The bound proteins were separated by SDS-PAGE and
visualized by silver-staining (Fig. 2). The use of compound 2
derived matrix led to the detection of three distinct protein bands,
two of which at higher molecular weights also being present in the
control (Fig. 2A). Trypsin digestion and peptide sequencing by
LC/ESI/MS/MS-QTOF mass spectrometry identified the spe-
cific band at ,40 kDa as adenosine kinase of T. b. rhodesiense
(TbrAK, expected size of 38.1 kDa; score 141), whereas the other
two corresponded to human keratin (score 392 and 752). Affinity
matrix prepared with compound 3 did not isolate a protein
different to the back ground signals identified as human keratin
(Fig. 2B). In contrast, immobilized derivative 4 behaved
differently, and more distinct proteins were isolated. Subsequent
protein analysis found human keratin in most cases. One distinct
protein band not visible in the control was identified as glycosomal
T. b. rhodesiense glyceraldehyde-3-phosphate dehydrogenase
(TbrGAPDH, expected size of 39.3 kDa; score 87) (Fig. 2C).
Protein bands isolated on the control matrices were considered to
bind unspecifically and were not further examined.
Production of recombinant TbrGAPDH and TbrAK
For chemical validation of both TbrGAPDH and TbrAK,
proteins were produced recombinantly in sufficient amounts. The
gapdh gene, kindly provided by Prof. Paul A. M. Michels (University
of Louvain, Brussels, Belgium), was subcloned into an expression
vector that yielded 10–15 mg of highly pure (.99%) TbrGAPDH
per liter culture (Fig. S2A). Since the ak is a tandem gene coding for
two almost identical (99% identity, 4 out of 345 amino acids
different) adenosine kinases (SwissProt entries Q584S0 and
Q584S6) it was necessary to determine which one had been
isolated. The detailed analysis of the fragments resulting from the
trypsin digestion revealed that peptide DIESTVLATK can be
unambiguously allocated to the Q584S0 sequence, thus this isoform
of TbrAK was cloned, expressed and purified to homogeneity and
resulted in 40–50 mg of soluble and highly pure (.99%) TbrAK
per liter culture (Fig. S2B). Both TbrGAPDH and TbrAK were
active and could be used for subsequent analyses.
Compound 1 enhances TbrAK activity
TbrAK activity in absence and presence of the compounds was
analyzed using an HPLC protocol that allowed the separation of
adenosine, AMP, ADP, and ATP. Surprisingly, the assay revealed
a 2.5-fold (absolute value: 24563%) and 1.7-fold (17465%)
increase of enzyme activity in presence of 50 mM of compound 1
and 2, respectively (Fig. 3; Fig. S3). A less pronounced but still
significant effect (two-tailed t-test, p,0.01) was observed for
compound 3 and 4 at 50 mM with an apparent increase of activity
to 11061% and 10961%, respectively. The negative control
(compound 5) did not have this activating effect on TbrAK activity
(see Fig. S3). To validate the activity measured at a single
concentration, the concentration dependence of the effect was
analyzed. The hyperactivation effect is found to be concentration
dependent for compounds 1, 2 and 4 (Fig. 3). The results clearly
show that under the experimental conditions a half maximal
effective concentration (EC50) of 38.960.9 mM for compound 1 is
determined. Although the solubility limits prevented any EC50
determination regarding compounds 2 and 4 (Fig. 3), the
concentration dependence, thus the specificity of the effect is
proven also for these compounds. Interestingly, although com-
pound 3 appeared to activate TbrAK at a low level (11061%) it
does not exhibit any concentration dependence when assayed up
to concentrations corresponding to its maximum solubility, thus
behaved like the inactive control compound 5 (Fig. 3).
The EC50 of found for compound 1 seemed to contrast the IC50
of 1.0 mM on the parasite. We reasoned that the experimental
conditions of the HPLC assay may be at the origin of the high
EC50 value, thus we analyzed the activating effect of compound 1
using the more sensitive radiometric assay, which allowed the
analysis at low substrate and enzyme concentrations (Supporting
Figure 2. SDS-PAGE (12%) analysis of proteins retained by the affinity matrices. Panel A: Matrix linked with derivative 2. Panel B: Matrix
linked with derivative 3. Panel C: Matrix linked with derivative 4. Samples of T. b. rhodesiense lysate (200 mg total protein content) were incubated
with either 40 ml control beads (lanes a) or 40 ml affinity beads (lanes b). Proteins retained by the matrices were directly separated by SDS-PAGE.
Arrows indicate protein bands resulting from the compound derived matrices. AK: adenosine kinase of T. b. rhodesiense; GAPDH: glycosomal
glyceraldehyde-3-phosphate dehydrogenase of T. b. rhodesiense; K: human keratin. Molecular mass markers are shown on the left.
doi:10.1371/journal.pntd.0000506.g002
TbrAK as Putative Target with Novel Mechanism
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assay. Indeed, the hyperactivation effect was concentration
dependent with an EC50 of 38612 nM for compound 1 (Fig.
S4). This value is well in line with the observed affinity (KD of
75620 nM and 497634 nM for the high and low affinity binding
site, respectively) of compound 1 towards TbrAK, and the
observed IC50 of 1.0 mM in the in-vitro whole cell assay.
In contrast to adenosine kinase, TbrGAPDH activity was not
influenced by any of the compounds with respect to forward and
reverse reaction (Fig. S5) when measured at concentrations up to
50 mM (limit given due to strong absorption at the wavelength
applied), suggesting that TbrGAPDH could be considered as a
false positive hit.
Compound 1 is binding specifically to TbrAK
Specific binding of compound 1 with respect to the isolated
proteins was analyzed by two methods. Thermal stability of
proteins and protein complexes can be evaluated by CD
spectroscopy. Due to the fact that the complex of a ligand bound
to the native conformation of a protein will have a higher thermal
stability than the empty protein [14], an increased melting point
(Tm) of the protein in presence of a ligand will give evidence for
specific binding. Indeed, apo TbrAK melted at 43.160.4uC and
was stabilized by the control compound adenosine with a DTm of
7.6uC( T m 50.760.2uC) (Table 1). In a similar way, compound 1
and 2 were able to increase thermal stability by a DTm of 4.8uC
(Tm 47.960.1uC) and a DTm of 2.8uC( T m of 45.960.4uC),
respectively, thus confirming specific binding for compound 1 to
the enzyme (Table 1). Compound 3, 4, and 5 did not stabilize the
protein when added at 50 mM (Table 1).
As an orthogonal method to CD we used isothermal titration
calorimetry (ITC) to analyze binding of compound 1 to TbrAK.
The titration of TbrAK with compound 1 revealed a complex and
enthalpy driven binding mode with two molecules of 1 binding to
one molecule of enzyme. Exothermic binding heats were corrected
for heats of dilution, integrated and plotted against the molar ratio
of 1 and enzyme (trace I in Fig. 4). The binding isotherm was best
described using a non-linear least square fit assuming a two-sites
non-interacting binding model. Subsequent analysis revealed a
Figure 3. Concentration dependence of the activation effect
for compounds 1 to 5 in the range of 1–750 mM. Increasing
concentrations of compound 1 (N) gives a sigmoid saturation curve for
TbrAK activation, yielding an EC50 value of 38.960.9 mM. A similar trend
is observed for compound 2 (m), but due to limited solubility at
concentrations .50 mM the EC50 could not be determined. Compound
4 (&) started activating TbrAK in a concentration dependent manner
without reaching a maximum at the solubility limiting concentration of
750 mM. Compound 3 (¤) and the control compound 5 (w) did not
activate TbrAK under identical conditions. Values are reported as %
activity derived from the transformation rate. For comparative reasons
the activity recorded in absence of compound was set to 100%.
Standard deviations are represented by vertical bars. The mean of three
independent measurements is reported.
doi:10.1371/journal.pntd.0000506.g003
Table 1. Thermal stability assay regarding TbrAK in absence
and presence of compounds and substrates.
Tm [uC]
a DTm [uC]
TbrAK 43.160.4 –
TbrAK+compound 1 47.960.1 4.8
TbrAK+compound 2 45.960.4 2.8
TbrAK+compound 3 42.860.2 20.3
TbrAK+compound 4 43.260.1 0.1
TbrAK+compound 5 43.460.1 0.3
TbrAK+ATP 42.860.1 20.3
TbrAK+adenosine 50.760.2 7.6
aValues represent the average of three independent experiments.
doi:10.1371/journal.pntd.0000506.t001
Figure 4. Specific binding of compound 1 to TbrAK measured
by ITC. The top panel shows heat signals upon 27 injections of
compound 1 (trace I) or control compound 5 (trace II) into the sample
cell containing 7 mM TbrAK. The binding isotherm obtained by
integration and normalization of the raw data and by correction for
the heat of ligand dilution is shown on the lower panel. The solid line
represents the non-linear least square fit based on a two-sites non-
interacting binding model. Compound 1 binds to TbrAK via a high
affinity binding site with a KD of 75620 nM and a DHbind of
23.0560.77 kcal/mol, and a low affinity site exhibiting a KD of
497634 nM and a DHbind of 21.1360.24 kcal/mol. No specific heat
release was shown for the negative control (trace II). The mean of three
independent experiments are reported.
doi:10.1371/journal.pntd.0000506.g004
TbrAK as Putative Target with Novel Mechanism
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23.0560.77 kcal/mol, while the low affinity site exhibited a KD
of 497634 nM and a DHbind of 21.1360.24 kcal/mol. The
negative control using compound 5 showed no specific heat release
(see trace II in Fig. 4).
In contrast to TbrAK, TbrGAPDH was not significantly
stabilized by any of the compounds, while in presence of the
substrate NAD
+ or DL-GAP thermal stability increased (see Table
S1). In agreement with above TbrGAPDH activity measurement,
no binding of the compounds to the protein was observed, clearly
indicating that TbrGAPDH is a false positive hit. Therefore, this
enzyme was not further validated.
Compound 1 interferes with substrate-inhibition of
TbrAK
A common property of adenosine kinases from various
organisms is their control via a substrate-inhibition mechanism
[15–18], and recently it was shown that T. brucei AK was inhibited
by high adenosine concentrations to prevent non-physiologically
high intracellular purine nucleotide levels [19]. This prompted us
to analyze the influence of compound 1 toward TbrAK with
respect to substrate transformation by determining the kinetic
parameters in absence and presence of the activator. TbrAK
activity was measured at increasing adenosine concentrations and
a fixed concentration of 167 mM ATP. All data are given in
Table 2. Adenosine kinetics in absence of compound 1 displayed
non-hyperbolic progress plots (Fig. 5). After increasing activity up
to a maximum at 2–3 mM adenosine, the enzyme activity declined
at higher substrate concentrations which is a typical finding for
substrate-inhibition. Thus the observed kinetic data were fit to the
substrate-inhibition model [10]. Indeed, a good fit was obtained
for all data points, yielding a Km of 0.9960.05 mM and a Vmax of
19.6060.33 nM/min. kcat and catalytic efficiency were found to
be 0.3760.01 s
21 and 0.3860.01 mM
21 s
21, respectively.
TbrAK was inhibited by adenosine with a Ki of 6.161.4 mM.
In contrast, in presence of compound 1 substrate-inhibition was
strongly reduced (Fig. 5), and adenosine inhibited TbrAK with a
more than ten-fold increased Ki value (78.462.2 mM). While Km
(0.6560.04 mM), Vmax (14.2060.14 mM) and kcat
(0.0.2760.01 s
21) were slightly reduced in presence of compound
1, the catalytic efficency kcat/Km (0.4260.01 mM
21 s
21) did not
change significantly (Table 2).
Down-regulation of adenosine kinase in T. b. brucei
counteracts compound 1 activity
The proposed mechanism of action for compound 1, hyper-
activation of TbrAK, implies that down-regulation of TbrAK
activity counteracts compound 1 toxicity. This hypothesis was
addressed by RNAi-mediated silencing of TbAK expression, using
bloodstream-form T. b. brucei that express in a tetracycline-
inducible manner a stem-loop construct targeted against TbAK
[11]. TbAK knock-down has been confirmed recently on the RNA
and protein level [11,19]. The addition of tetracycline reduced the
sensitivity of TbAK RNAi cells to compound 1, raising the IC50
from 131643 nM to 271625 nM (two-tailed t-test, p,0.05;
Fig. 6). The negative control (compound 5) did not exhibit any
IC50 difference in the induced and non-induced TbAK RNAi
cells.
Figure 5. Representative plots for TbrAK kinetics (AMP
formation) with respect to adenosine in absence (#) and
presence (N) of compound 1 (33 mM). Adenosine strongly inhibits
TbrAK at concentrations .2 mM and follows typical substrate-inhibition
kinetics. In contrast, compound 1 abolishes substrate-inhibition. The
solid lines indicate the fit of the raw data with the substrate-inhibition
model (see Table 2 for fitting results).
doi:10.1371/journal.pntd.0000506.g005
Table 2. Parameters derived from TbrAK kinetics with respect
to adenosine in absence and presence of compound 1.
no compound compound 1
Km [mM] 0.9960.05 0.6560.04
Vmax [nM/min] 19.6060.33 14.2060.14
kcat [s
21] 0.3760.01 0.2760.01
kcat/Km [mM
21 s
21] 0.3860.01 0.4260.01
Ki adenosine [mM] 6.161.4 78.462.2
The substrate-inhibition model was applied to fit the raw data; values represent
the average of three independently recorded series with each data point
measured in triplicate.
doi:10.1371/journal.pntd.0000506.t002
Figure 6. Dose-response curve for parasite growth in presence
of compound 1. RNAi-mediated silencing of TbAK expression by
tetracycline (N) reduces sensitivity of TbAK RNAi cells to compound 1
when compared to non-induced cells (#), raising the IC50 from
131643 nM to 271625 nM (two-tailed t-test, p,0.05).
doi:10.1371/journal.pntd.0000506.g006
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A chemical proteomics approach was applied to isolate and
identify the cellular target of compound 1. To this end, three of its
amino-derivatives where immobilized, and the corresponding affinity
matrixes were used to pull down potential targets. Indeed, this
approach afforded multiple proteins. Most of them could be detected
in both the control and the isolation experiment (Fig. 2) and thus
could be considered as unspecific bound protein. Amongst other,
human keratin wasthe predominant contamination which turned out
to be present under any circumstances, and it was even found in new
batches of matrix that werestored in sealed containers before first use.
Remarkably, we observed differences regarding inter- and intrabatch
reproducibility. Experiments were always reproducible with respect
to background when the same batch of activated matrix was used
whilechangingtoanewbatchledtoalteredbackground(seelaneain
Fig. 2A,B,C). However, two distinct proteins not appearing in the
control reaction were identified as TbrGAPDH and TbrAK, two
trypanosomal enzymes that are involved in parasite glycolysis and
purine salvage, respectively. Both enzymes were cloned and
recombinantly expressed.
The subsequent chemical validation of both enzymes revealed
that TbrGAPDH activity was neither affected by compound 1
(Fig. S5) nor specific binding of 1 toward the enzyme was observed
(Table S1), suggesting TbrGAPDH to be a false positive hit. As a
matter of fact, due the highly charged nature and its high
abundance in the parasite this particular target has a strong
tendency to be isolated by affinity chromatography [20–22].
In contrast and unexpectedly, the HPLC activity assay revealed
that compound 1 strongly activated TbrAK activity. A similar
effect was measured for compound 2, while derivatives 3 and 4
only exhibited very low though significant activity toward TbrAK
(Fig. S3). Compound 1, 2 and 4 activated TbrAK in a
concentration dependent manner, yielding an EC50 of
38.960.9 mM for compound 1 (Fig. 3). While the EC50 of 2
and 4 could not be determined due to solubility problems, it can
be estimated that they would be higher than the one observed with
compound 1 (Fig. 3). The observed data for compound 1 and 2
correlate well with formerly determined in-vitro data that showed
an IC50 of 1.0 mM and 17.7 mM against blood stage T.b. rhodesiense
[7], and also with the fact that compound 2 was able to bind the
target. TbrAK activation by derivative 4 was concentration
dependent (EC50.750 mM, Fig. 3) which corresponds very well to
the low activation capacity at 50 mM (10961%, Fig. S3), (see text
below for discussion of this issue).
Specific binding could be verified for compounds 1 and 2 by the
thermal stability assay as shown by the Tm increase (Table 1). For
the least active compounds (3 and 4) no stabilization was observed.
While this finding is in line with the lack of activity at all
concentrations tested for compound 3, it seems to contrast the
concentration dependence of derivative 4. However, taking into
consideration the small activating effect, the concentration
dependence and the unchanged Tm in presence of compound 4,
it is likely to assume that this derivative binds with low affinity to
the target. Unfortunately, the limited solubility prevented further
investigations at concentrations .750 mM regarding Tm as well as
binding affinity due to the technical limits given by CD
spectroscopy and ITC. As expected the negative control
(compound 5) did neither activate TbrAK nor improve thermal
stability, giving further evidence for specific binding of compound
1 and 2. In addition, binding of compound 1 to TbrAK could be
confirmed by ITC which revealed enthalpy driven high affinity
interaction. Interestingly, it appears that two molecules of the
activator are bound per molecule of enzyme. Under the same
conditions control compound 5 did not bind to the enzyme and
produced only unspecific heat signals related to protein and ligand
dilution in the sample cell (Fig. 4).
On the target level it is evident that the additional amino group
in derivative 2 only moderately interferes with the activating effect,
thus binding to TbrAK seems disturbed but still productive. In
contrast, replacing the oxygen in the morpholine moiety by
nitrogen (compound 4) strongly increases EC50 at least 20 fold,
suggesting that binding to TbrAK is severely impaired with this
derivative. Finally, a substitution on the pyrazole moiety
(compound 3) leads to very low and concentration independent
activity. These observations are well in line with the fact that none
of these two derivatives stabilized TbrAK in the thermal stability
assay (Table 1). On the parasite level the situation is different.
Regarding derivative 3, the very low activity toward the isolated
enzyme while exhibiting an IC50 of 10.3 mM on the parasite [7],
leads to the conclusion that toxicity is not conferred by TbrAK but
by another yet to be determined target. For compound 4 the
situation appears more complex. The observed concentration
dependence gives strong evidence for it acting against TbrAK, but
its potentially low affinity and the low activation capacity (EC50
.750 mM) toward the target would lead to reduced trypanocidal
activity. However, derivative 4 is highly potent in the parasite
assay (IC50 of 1.1 mM) [7]. It is therefore likely that the
trypanocidal effect of compound 4 is based on a combination of
target specific activity, and/or possible off-target activity, and
increased general toxicity [7]. In addition, increased accumulation
within the parasite compared to compound 1 could contribute to
the strong effect, while reduced cell uptake may explain the
difference in potency of derivative 2 on the isolated target. Thus,
taking into consideration the above observations and the complete
lack of activity of the control compound 5 in all experiments, we
can state that the intact morpholine/pyrazole moiety represents an
important part of the pharmacophore, while the introduction of
basic amino groups may impair the activating effect due to altered
physico-chemical properties on target and/or parasite level.
To further validate TbrAK as the potential target of compound
1 we investigated parasite sensitivity toward compound 1 under
conditions of reduced intracellular adenosine kinase levels. To this
end, parasite viability of a knock-down mutant was measured.
Indeed, as expected for a mechanism of action based on
overactivation of TbrAK by compound 1, the sensitivity of
TbrAK silenced parasite cells decreased as shown by the IC50
raising from 131643 nM to 271625 nM (two-tailed t-test,
p,0.05). Although the applied tetracycline-inducible system is
leaky and not capable to provide a complete knock-out [11] the
observed difference is statistically significant, demonstrating that
the toxic effect of compound 1 is adenosine kinase dependent.
Although we cannot rule out that compound 1 could interact with
other targets in the cell that may not be amenable to the pull down
approach (e.g. cytoskeleton, DNA, interference with mitochondrial
electron transport), the line of evidence strongly supports TbrAK
to represent the putative cellular target.
A first step toward the elucidation of the mechanism of action
with respect to the activating effect was accomplished by
determination and analysis of kinetic parameters with respect to
substrate transformation in absence and presence of the activator
1. TbrAK activity is strongly inhibited by its substrate adenosine
(Ki of 6.161.4 mM), thus it follows substrate-inhibition kinetics.
This is a common characteristic of adenosine kinases isolated from
various sources [15–18] and has also been described for TbrAK
very recently [19]. Under the experimental conditions applied, the
Ki of adenosine increased more than ten-fold to a value of
78.462.2 mM when compound 1 was present, resulting in strongly
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www.plosntds.org 7 August 2009 | Volume 3 | Issue 8 | e506reduced substrate-inhibition (Fig. 5) while the kinetic parameters
remained almost identical. Taken together, the results suggest that
the mechanism for trypanocidal activity functions via hyperactiva-
tion of adenosine kinase. There are two principally different
explanations for the toxic effect of hyperactivation. Uncontrolled
TbrAK activity could lead to purine imbalance within the parasite,
thus interfering with the vital purine salvage pathway, the
nucleotide pool and subsequently nucleic acid formation. Prece-
dence for this mechanism comes from E. coli, where high adenine
concentrations cause a cytotoxic [ATP]/[GTP] imbalance [23].
Alternatively, excessive adenosine kinase activity may use up the
existing adenosine/ATP pools and lead to adenosine depletion
and ATP burn-out. Interestingly, cell death upon hydrolysis of
ATP reserves due to mislocalization of glycosomal hexokinase to
the cytosol has already been observed for T. brucei [24,25].
Whereas hyperactivation as a mechanism of action is well
known from drugs targeting cell signaling, e.g. acetylcholine
receptor agonists, it represents a novel and hitherto unexplored
concept for compounds targeting metabolic enzymes. The
cytotoxic hyperactivation of adenosine kinase does not only
provide an opportunity for the chemotherapy of sleeping sickness,
but when explored against other pathogens or tumor cells,
hyperactivation of metabolic key enzymes may well find further
pharmacological applications.
Supporting Information
Figure S1 Affinity matrix preparation. 4-[4-(5-morpholine-4-yl-
1H-pyrazol-3-yl)-phenoxy]-phenylamine (2), 4-[5-morpholine-4-
yl-3-(4-phenoxyphenyl)-pyrazol-1-yl]phenylamine (3) and 1-[5-(4-
phenoxy-phenyl-2H-pyrazol-3-yl]piperazine (4) were coupled to
epoxy-activated agarose consisting of a 12-atoms spacer (1,4-
bis(2:3-epoxypropoxy)butane) to form affinity matrices A, B, and
C, respectively. The agarose beads are shown as spheres.
Found at: doi:10.1371/journal.pntd.0000506.s001 (0.04 MB PDF)
Figure S2 SDS-PAGE analysis of expression and purification of
recombinant proteins. Panel A: TbrGAPDH, panel B: TbrAK. Lane
1: marker proteins; lane 2: soluble fraction of crude extract; lane 3:
final pure protein. The expected molecular weights for TbrGAPDH
(including His6-tag) and TbrAK are 41.2 kDa and 38.0 kDa,
respectively. Molecular mass of the markers are shown on the left.
Found at: doi:10.1371/journal.pntd.0000506.s002 (0.14 MB PDF)
Figure S3 Activation properties of compounds 1 to 5 measured
by HPLC and monitoring ADP formation and ATP consumption.
TbrAK (0.7 mM) was incubated for 10 min at 37uC in absence or
presence of 50 mM compound. Compound 1 and 2 lead to strong
TbrAK activation with compound 1 showing up to a 2.5 fold
increase. The corresponding values are: 10062% without
compound (TbrAK), 24563% (compound 1), 17465% (com-
pound 2), 11061% (compound 3), 10961% (compound 4), and
10262% for the negative control (compound 5). Values are
reported as % activity derived from ADP/ATP ratios. For
comparative reasons the activity recorded in absence of compound
(column labeled TbrAK) was set to 100%. The mean of three
independent experiments is reported.
Found at: doi:10.1371/journal.pntd.0000506.s003 (0.02 MB PDF)
Figure S4 Concentration dependence of the activation effect of
compound 1 analyzed by a radiometric assay. Increasing
concentrations of compound 1 yield a sigmoid saturation curve
for TbrAK activation with an EC50 value of 38612 nM. Values
are reported as % activity derived from the transformation rate.
For comparative reasons the activity recorded in absence of
compound was set to 100%. The mean of four independent
measurements is reported.
Found at: doi:10.1371/journal.pntd.0000506.s004 (0.02 MB PDF)
Figure S5 UV-spectroscopic analysis of TbrGAPDH activity
(reverse reaction) in absence and presence of compounds 1 to 5 at
50 mM concentration. TbrGAPDH (60 nM) was incubated for
10 min at 25uC in absence or presence of each compound. None
of the compounds either showed significantly increased or
decreased activity at concentrations up to 50 mM. Values are
reported as % activity derived from the transformation rate. For
comparative reasons the activity recorded in absence of compound
(column labeled TbrGAPDH) was set to 100%. The mean of three
independent experiments is reported.
Found at: doi:10.1371/journal.pntd.0000506.s005 (0.02 MB PDF)
Table S1 Thermal stability assay regarding TbrGAPDH in
absence and presence of compounds and substrates.
Found at: doi:10.1371/journal.pntd.0000506.s006 (0.07 MB PDF)
Text S1 Supporting information with respect to origin of
supplies, protocols for purification of recombinant proteins, the
spectroscopic assay for TbrGAPDH, the radiometric assay for
TbrAK, and the thermal denaturation assay.
Found at: doi:10.1371/journal.pntd.0000506.s007 (0.09 MB PDF)
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